Brief Report: Autoantibodies to DNA mismatch repair enzymes in polymyositis/dermatomyositis and other autoimmune diseases: A possible marker of favorable prognosis

Yoshinao Muro, Ran Nakashima, Yuji Hosono, Kazumitsu Sugiura, Tsuneyo Mimori, Masashi Akiyama

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Objective Myositis-specific autoantibodies (MSAs) are useful tools for identifying clinical subsets of patients with idiopathic inflammatory myopathies (IIMs). There have been few reports on antibodies to some DNA mismatch repair enzymes (MMREs) in patients with IIMs. This study was undertaken to determine the frequencies and clinical associations of antibodies to 7 types of MMREs (MLH1, MLH3, MSH2, MSH3, MSH6, PMS1, and PMS2) in patients with IIMs and other systemic autoimmune diseases.

Methods Clinical data and serum samples were collected from 239 Japanese patients with IIMs (147 with adult dermatomyositis, 13 with juvenile dermatomyositis, 57 with polymyositis, and 22 with myositis overlap syndrome). One hundred patients with other diseases, including 40 with systemic lupus erythematosus (SLE), were assessed as disease controls. The presence of anti-MMRE antibodies in serum was examined by immunoprecipitation, enzyme-linked immunosorbent assay, and immunoprecipitation/Western blotting.

Results Anti-MMRE antibodies were found in 15 patients with IIMs and 3 patients with SLE. They were restricted to MLH1, PMS1, MSH2, and PMS2, with simultaneous positivity for more than one of these antibodies occurring in some patients. Nine IIM patients with anti-MMREs also had other MSAs and their associated clinical features. All patients with anti-MMREs were still living at the time of the present analysis.

Conclusion Anti-MMRE antibodies, which often coexist with other MSAs, may be serologic markers for good prognosis in IIMs.

Original languageEnglish
Pages (from-to)3457-3462
Number of pages6
JournalArthritis and Rheumatology
Volume66
Issue number12
DOIs
Publication statusPublished - 01-01-2014
Externally publishedYes

Fingerprint

DNA Repair Enzymes
Myositis
DNA Mismatch Repair
Dermatomyositis
Autoantibodies
Autoimmune Diseases
Antibodies
Enzymes
Immunoprecipitation
Systemic Lupus Erythematosus
Polymyositis
Serum
Western Blotting

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Rheumatology
  • Immunology

Cite this

@article{33c0f7315f574f469e5bd10b0e3860b1,
title = "Brief Report: Autoantibodies to DNA mismatch repair enzymes in polymyositis/dermatomyositis and other autoimmune diseases: A possible marker of favorable prognosis",
abstract = "Objective Myositis-specific autoantibodies (MSAs) are useful tools for identifying clinical subsets of patients with idiopathic inflammatory myopathies (IIMs). There have been few reports on antibodies to some DNA mismatch repair enzymes (MMREs) in patients with IIMs. This study was undertaken to determine the frequencies and clinical associations of antibodies to 7 types of MMREs (MLH1, MLH3, MSH2, MSH3, MSH6, PMS1, and PMS2) in patients with IIMs and other systemic autoimmune diseases.Methods Clinical data and serum samples were collected from 239 Japanese patients with IIMs (147 with adult dermatomyositis, 13 with juvenile dermatomyositis, 57 with polymyositis, and 22 with myositis overlap syndrome). One hundred patients with other diseases, including 40 with systemic lupus erythematosus (SLE), were assessed as disease controls. The presence of anti-MMRE antibodies in serum was examined by immunoprecipitation, enzyme-linked immunosorbent assay, and immunoprecipitation/Western blotting.Results Anti-MMRE antibodies were found in 15 patients with IIMs and 3 patients with SLE. They were restricted to MLH1, PMS1, MSH2, and PMS2, with simultaneous positivity for more than one of these antibodies occurring in some patients. Nine IIM patients with anti-MMREs also had other MSAs and their associated clinical features. All patients with anti-MMREs were still living at the time of the present analysis.Conclusion Anti-MMRE antibodies, which often coexist with other MSAs, may be serologic markers for good prognosis in IIMs.",
author = "Yoshinao Muro and Ran Nakashima and Yuji Hosono and Kazumitsu Sugiura and Tsuneyo Mimori and Masashi Akiyama",
year = "2014",
month = "1",
day = "1",
doi = "10.1002/art.38866",
language = "English",
volume = "66",
pages = "3457--3462",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "12",

}

Brief Report : Autoantibodies to DNA mismatch repair enzymes in polymyositis/dermatomyositis and other autoimmune diseases: A possible marker of favorable prognosis. / Muro, Yoshinao; Nakashima, Ran; Hosono, Yuji; Sugiura, Kazumitsu; Mimori, Tsuneyo; Akiyama, Masashi.

In: Arthritis and Rheumatology, Vol. 66, No. 12, 01.01.2014, p. 3457-3462.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Brief Report

T2 - Autoantibodies to DNA mismatch repair enzymes in polymyositis/dermatomyositis and other autoimmune diseases: A possible marker of favorable prognosis

AU - Muro, Yoshinao

AU - Nakashima, Ran

AU - Hosono, Yuji

AU - Sugiura, Kazumitsu

AU - Mimori, Tsuneyo

AU - Akiyama, Masashi

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Objective Myositis-specific autoantibodies (MSAs) are useful tools for identifying clinical subsets of patients with idiopathic inflammatory myopathies (IIMs). There have been few reports on antibodies to some DNA mismatch repair enzymes (MMREs) in patients with IIMs. This study was undertaken to determine the frequencies and clinical associations of antibodies to 7 types of MMREs (MLH1, MLH3, MSH2, MSH3, MSH6, PMS1, and PMS2) in patients with IIMs and other systemic autoimmune diseases.Methods Clinical data and serum samples were collected from 239 Japanese patients with IIMs (147 with adult dermatomyositis, 13 with juvenile dermatomyositis, 57 with polymyositis, and 22 with myositis overlap syndrome). One hundred patients with other diseases, including 40 with systemic lupus erythematosus (SLE), were assessed as disease controls. The presence of anti-MMRE antibodies in serum was examined by immunoprecipitation, enzyme-linked immunosorbent assay, and immunoprecipitation/Western blotting.Results Anti-MMRE antibodies were found in 15 patients with IIMs and 3 patients with SLE. They were restricted to MLH1, PMS1, MSH2, and PMS2, with simultaneous positivity for more than one of these antibodies occurring in some patients. Nine IIM patients with anti-MMREs also had other MSAs and their associated clinical features. All patients with anti-MMREs were still living at the time of the present analysis.Conclusion Anti-MMRE antibodies, which often coexist with other MSAs, may be serologic markers for good prognosis in IIMs.

AB - Objective Myositis-specific autoantibodies (MSAs) are useful tools for identifying clinical subsets of patients with idiopathic inflammatory myopathies (IIMs). There have been few reports on antibodies to some DNA mismatch repair enzymes (MMREs) in patients with IIMs. This study was undertaken to determine the frequencies and clinical associations of antibodies to 7 types of MMREs (MLH1, MLH3, MSH2, MSH3, MSH6, PMS1, and PMS2) in patients with IIMs and other systemic autoimmune diseases.Methods Clinical data and serum samples were collected from 239 Japanese patients with IIMs (147 with adult dermatomyositis, 13 with juvenile dermatomyositis, 57 with polymyositis, and 22 with myositis overlap syndrome). One hundred patients with other diseases, including 40 with systemic lupus erythematosus (SLE), were assessed as disease controls. The presence of anti-MMRE antibodies in serum was examined by immunoprecipitation, enzyme-linked immunosorbent assay, and immunoprecipitation/Western blotting.Results Anti-MMRE antibodies were found in 15 patients with IIMs and 3 patients with SLE. They were restricted to MLH1, PMS1, MSH2, and PMS2, with simultaneous positivity for more than one of these antibodies occurring in some patients. Nine IIM patients with anti-MMREs also had other MSAs and their associated clinical features. All patients with anti-MMREs were still living at the time of the present analysis.Conclusion Anti-MMRE antibodies, which often coexist with other MSAs, may be serologic markers for good prognosis in IIMs.

UR - http://www.scopus.com/inward/record.url?scp=84912023291&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84912023291&partnerID=8YFLogxK

U2 - 10.1002/art.38866

DO - 10.1002/art.38866

M3 - Article

C2 - 25186186

AN - SCOPUS:84912023291

VL - 66

SP - 3457

EP - 3462

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 12

ER -